Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio Martin

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Journal of Medicinal Chemistry|April 27, 2021
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral LeishmaniasisMichael Thomas, Stephen Brand, Manu De Rycker, et al.
Investigative Radiology|January 27, 2009
Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trialRenate Hammerstingl, Gerhard Adam, Juan-Ramon Ayuso, et al.
Journal of the American Academy of Dermatology|October 10, 2025
Distinctive genomic features of hydroa vacciniforme lymphoproliferative disorder in Latin American patients: A multicenter multi-omics studyAleksander Luniewski, Margaret Moore, Eli S Williams, et al.
Science Translational Medicine|December 13, 2023
Short-course combination treatment for experimental chronic Chagas diseaseSilvia González, Richard J Wall, John Thomas, et al.
Journal of Medicinal Chemistry|July 28, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome InhibitorsMichael G Thomas, Kate McGonagle, Paul Rowland, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionSusan Wyllie, Stephen Brand, Michael Thomas, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Journal of Medicinal Chemistry|April 27, 2021
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral LeishmaniasisMichael Thomas, Stephen Brand, Manu De Rycker, et al.
Investigative Radiology|January 27, 2009
Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trialRenate Hammerstingl, Gerhard Adam, Juan-Ramon Ayuso, et al.
Journal of the American Academy of Dermatology|October 10, 2025
Distinctive genomic features of hydroa vacciniforme lymphoproliferative disorder in Latin American patients: A multicenter multi-omics studyAleksander Luniewski, Margaret Moore, Eli S Williams, et al.
Science Translational Medicine|December 13, 2023
Short-course combination treatment for experimental chronic Chagas diseaseSilvia González, Richard J Wall, John Thomas, et al.
Journal of Medicinal Chemistry|July 28, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome InhibitorsMichael G Thomas, Kate McGonagle, Paul Rowland, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionSusan Wyllie, Stephen Brand, Michael Thomas, et al.
Pageof 5